Stockhub

Abliva AB: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

16 August 2022

  • curprev 05:4105:41, 16 August 2022‎ Paris talk contribs‎ 897 bytes +897‎ Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain i..." Tag: Visual edit: Switched
Retrieved from ‘https://stockhub.co/research/Abliva_AB’